D.E. Shaw & Co
EBS icon

D.E. Shaw & Co’s Emergent Biosolutions EBS Stock Holding History

D.E. Shaw & Co’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,100
Closed -$258K – 5023
2021
Q2 		$258K Buy
+4,100
New +$263K ﹤0.01% 4345

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co's EBS Position: Q1 2026 in Review

D.E. Shaw & Co increased its Emergent Biosolutions (EBS) stake by 39% in Q1 2026, buying an estimated $2.91M and bringing the position to 1,003,912 shares worth $8.33M. The position accounts for 0.01% of the portfolio, ranked #1793.

D.E. Shaw & Co first reported a position in EBS in Q2 2013 and has held it in 50 quarters since. The position peaked at $47.8M in Q1 2022. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • D.E. Shaw & Co held 1,003,912 shares of Emergent Biosolutions worth $8.33M as of Q1 2026.
  • D.E. Shaw & Co bought 280,695 Emergent Biosolutions shares in Q1 2026, an estimated $2.91M.
  • Emergent Biosolutions made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1793 holding.
  • D.E. Shaw & Co first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 50 quarters since.
  • D.E. Shaw & Co's Emergent Biosolutions position peaked at $47.8M in Q1 2022.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.